Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

Northwestern University37 enrolled

Overview

The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Schizophrenia Schizoaffective Disorder Bipolar Disorder Major Depression

Interventions

genetic analysisPROCEDURE

genetic assay of blood sample drawn with patient's consent

genetic assayPROCEDURE

genetic assay of blood sample drawn with patient's consent

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder. Exclusion Criteria: Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.

Locations (1)

Psychiatric Hospital at Vanderbilt

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

We plan to compare the polymorphisms across schizophrenic patients and adults who do not have a diagnosed major mental illness. .

Time frame: single visit

Secondary Outcomes

We will also evaluate relationships between the polymorphism and past and current mental health among the non-diagnosed sample

Time frame: single visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.